Connor, Clark & Lunn Investment Management (CC&L)
AZN icon

Connor, Clark & Lunn Investment Management (CC&L)’s AstraZeneca AZN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-710,849
Closed -$131M – 1555
2025
Q4 		$131M Buy
710,849
+689,944
+3,300% +$121M 0.34% 67
2025
Q3 		$3.21M Buy
20,905
+10,657
+104% +$1.61M 0.01% 707
2025
Q2 		$1.43M Sell
10,248
-5,293
-34% -$742K 0.01% 952
2025
Q1 		$2.28M Buy
15,541
+2,903
+23% +$420K 0.01% 697
2024
Q4 		$1.66M Buy
12,638
+3,733
+42% +$523K 0.01% 786
2024
Q3 		$1.39M Buy
8,905
+2,511
+39% +$405K 0.01% 777
2024
Q2 		$997K Buy
6,394
+1,413
+28% +$213K ﹤0.01% 847
2024
Q1 		$675K Sell
4,981
-114
-2% -$15.1K ﹤0.01% 1018
2023
Q4 		$686K Sell
5,095
-615
-11% -$79.9K ﹤0.01% 964
2023
Q3 		$773K Sell
5,710
-203
-3% -$27.7K ﹤0.01% 902
2023
Q2 		$846K Buy
5,913
+283
+5% +$41.6K ﹤0.01% 844
2023
Q1 		$782K Sell
5,630
-35,249
-86% -$4.74M ﹤0.01% 780
2022
Q4 		$5.54M Sell
40,879
-81,859
-67% -$10.3M 0.03% 335
2022
Q3 		$13.5M Sell
122,738
-302,653
-71% -$38.4M 0.09% 168
2022
Q2 		$56.2M Buy
425,391
+422,088
+12,779% +$55.4M 0.34% 51
2022
Q1 		$438K Sell
3,303
-11,462
-78% -$1.37M ﹤0.01% 802
2021
Q4 		$1.72M Buy
+14,765
New +$1.74M 0.01% 566
2020
Q3 		– Sell
-55,175
Closed -$5.84M – 933
2020
Q2 		$5.84M Buy
+55,175
New +$5.7M 0.04% 270
2019
Q3 		– Sell
-56,450
Closed -$4.66M – 961
2019
Q2 		$4.66M Buy
56,450
+38,100
+208% +$2.99M 0.03% 300
2019
Q1 		$1.48M Sell
18,350
-20,000
-52% -$1.58M 0.01% 466
2018
Q4 		$2.91M Buy
+38,350
New +$2.99M 0.02% 356
2017
Q3 		– Sell
-63,050
Closed -$4.3M – 812
2017
Q2 		$4.3M Buy
+63,050
New +$4.12M 0.03% 285
2016
Q4 		– Sell
-21,522
Closed -$1.41M – 891
2016
Q3 		$1.41M Sell
21,522
-4,850
-18% -$317K 0.01% 419
2016
Q2 		$1.59M Hold
26,372
– – 0.01% 393
2016
Q1 		$1.49M Hold
26,372
– – 0.01% 385
2015
Q4 		$1.79M Sell
26,372
-2,700
-9% -$177K 0.02% 359
2015
Q3 		$1.85M Hold
29,072
– – 0.02% 309
2015
Q2 		$1.85M Sell
29,072
-500
-2% -$34.2K 0.02% 251
2015
Q1 		$2.02M Hold
29,572
– – 0.02% 232
2014
Q4 		$2.08M Hold
29,572
– – 0.02% 222
2014
Q3 		$2.11M Sell
29,572
-1,000
-3% -$73.2K 0.02% 212
2014
Q2 		$2.42M Sell
30,572
-15,900
-34% -$1.15M 0.02% 229
2014
Q1 		$3.33M Sell
46,472
-3,800
-8% -$245K 0.02% 209
2013
Q4 		$3.17M Sell
50,272
-21,379
-30% -$1.16M 0.02% 205
2013
Q3 		$3.83M Buy
+71,651
New +$3.6M 0.03% 133

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Connor, Clark & Lunn Investment Management (CC&L)'s AZN Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 710,849 shares — an estimated $131M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AZN in Q3 2013 and held it in 35 quarters. The position peaked at $131M in Q4 2025. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 710,849 AstraZeneca shares in Q1 2026, an estimated $131M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AstraZeneca in Q3 2013 and held it in 35 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s AstraZeneca position peaked at $131M in Q4 2025.
  • 1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.